Case reports and open trials have reported beneficial effects of divalproex in the treatment of posttraumatic stress disorder (PTSD). The objective of this study was to conduct a placebo-controlled study of the efficacy and tolerability of divalproex in chronic PTSD patients.
Methods
Patients were randomized to receive placebo or divalproex. The primary outcome measure was the Clinician Administered PTSD Scale (CAPS).
Results
Of 29 patients randomized, 16 received divalproex and 13 placebo. There were no significant differences between groups in mean change from baseline to end point (last observation carried forward) on the CAPS total score or subscales except for a significant decrease in avoidance/ numbing scores with placebo. The only significant difference in secondary outcomes was a greater improvement in Clinical Global Impression Scale-Severity favoring placebo.
Conclusions
Divalproex was not superior to placebo in this study. This could be due to lack of efficacy of divalproex in this population, inadequate sample size to detect differences, or other factors. Further study of divalproex is needed to better clarify the role of this agent in PTSD.
American Psychiatric Association. Practice guidelines for the treatment of patients with acute and chronic posttraumatic stress disorder. Arlington, VA: American Psychiatric Association; 2004.
2.
PTSD Treatment Guidelines Task Force. Guidelines for treatment of PTSD. J Trauma Stress. 2000;13: 539–588.
3.
Veterans Administration/Department of Defense Clinical Practice Guideline Working Group. Management of post-traumatic stress. Washington, DC: Veterans Health Administration, Department of Veterans Affairs and Health Affairs, Department of Defense; 2003. Office of Quality and Performance publication 10Q-CPG/PTSD-04.
4.
BallengerJCDavidsonJRLecrubierY. Consensus statement update on posttraumatic stress disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 2004, 65(suppl 1):55–62.
5.
Treatment of posttraumatic stress disorder. Expert Consensus Panels for PTSD. J Clin Psychiatry. 1999, 60(suppl 16):3–76.
6.
HertzbergMAButterfieldMIFeldmanME. A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry. 1999;45:1226–1229.
7.
TuckerPTrautmanRPWyattDB. Efficacy and safety of topiramate monotherapy in civilian post-traumatic stress disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68: 201–206.
8.
LindleySECarlsonEBHillK.A randomized double-blind, placebo-controlled trial of augmentation topiramate for chronic combat-related posttraumatic stress disorder. J Clin Psychopharmacol. 2007;27:677–681.
9.
DavidsonJRBradyKMellmanTA. The efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder. J Clin Psychopharmacol. 2007;27:85–88.
BerlantJvan KammenDP.Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: a preliminary report. J Clin Psychiatry. 2002;63:15–20.
12.
BerlantJL. Prospective open-label study of add-on and monotherapy topiramate in civilians with chronic nonhallucinatory posttraumatic stress disorder. BMC Psychiatry. 2004;4:24.
13.
TaylorFB. Tiagabine for posttraumatic stress disorder: a case series of 7 women. J Clin Psychiatry. 2003;64:1421–1425.
14.
ConnorKMDavidsonJRWeislerRH. Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment. Psychopharmacology (Berl). 2006;184:21–25.
15.
LipperSDavidsonJRGradyTA. Preliminary study of carbamazepine in posttraumatic stress disorder. Psychosomatics. 1986;27:849–854.
16.
WolfMEAlaviAMosnaimAD. Posttraumatic stress disorder in Vietnam veterans: clinical and EEG findings, possible therapeutic effects of carbamazepine. Biol Psychiatry. 1988;23:642–644.
17.
BremnerJDMletzkoTWelterS. Treatment of posttraumatic stress disorder with phenytoin: an open-label pilot study. J Clin Psychiatry. 2004;65: 1559–1564.
18.
HamnerMBBrodrickPSLabbateLA. Gabapentin in PTSD: a retrospective clinical series of adjunctive therapy. Ann Clin Psychiatry. 2001;113:141–146.
HarveyBHOosthuizenFBrandL. Stress-restress evokes sustained iNOS activity and altered GABA levels and NMDA receptors in rat hippocampus. Psychopharmacology (Berl). 2004;175:494–502.
21.
HarveyBHBothmaTNelA. Involvement of the NMDA receptor, NO-cyclic GMP, and nuclear factor K-beta in an animal model of repeated trauma. Human Psychopharmacology. 2005;20:367–373.
22.
ChambersRABremnerJDMoghaddamB. Glutamate and post-traumatic stress disorder: toward a psychobiology of dissociation. Semin Clin Neuropsychiatry. 1999;4:274–281.
23.
VaivaGThomasPDucrocqF. Low posttrauma GABA plasma levels as a predictive factor in the development of acute posttraumatic stress disorder. Biol Psychiatry. 2004;55:250–254.
24.
CunninghamMOWoodhallGLJonesRS. Valproate modifies spontaneous excitation and inhibition at cortical synapses in vitro. Neuropharmacology. 2003;45:907–917.
25.
GobbiGJaniriL.Sodium- and magnesium-valproate in vivo modulate glutaminergic and GABAergic synapses in the medial prefrontal cortex. Psychopharmacology (Berl). 2006;185:255–262.
26.
LaengPPittsRLLemireAL. The mood stabilizer valproic acid stimulates GABA neurogenesis from rat forebrain stem cells. J Neurochem. 2004;91:238–251.
27.
BeriganTRHolzgangA.Valproate as an alternative in post-traumatic stress disorder: a case report. Mil Med. 1995;160:318.
28.
SzymanskiHVOlympiaJ.Divalproex in post-traumatic stress disorder. Am J Psychiatry. 1991;148: 1086–1087.
OtteCWiedemannKYassouridisA. Valproate monotherapy in the treatment of civilian with noncombat-related posttraumatic stress disorder: an openlabel study. J Clin Psychopharmacol. 2004;24:106–108.
33.
DavisLLAmbroseSMNewellJM. Divalproex for the treatment of posttraumatic stress disorder: a retrospective chart review. International Journal of Psychiatry in Clinical Practice. 2005;9:278–283.
34.
HollanderETracyKASwannAC. Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology. 2003;28:1186–1197.
35.
DavisLLDavidsonJRWardLC. Divalproex in the treatment of post-traumatic stress disorder: a randomized, double-blind, placebo-controlled trial in a veteran population. J Clin Psychopharmacol. 2008;28:84–88.
36.
Diagnostic and statistical manual of mental disorders. 4th edition. Washington, DC: American Psychiatric Association; 1994.
37.
SpitzerRLWilliamsJBWGibbonM. Structured clinical interview for DSM-IV (SCID-IV). New York, NY: Biometric Research, New York State Psychiatric Institute; 1994.
38.
BlakeDDWeathersFWNagyLM. A clinician rating scale for assessing current and lifetime PTSD: the CAPS-1. Behavior Therapist. 1990;18:187–188.
39.
HorowitzMWilnerNAlvarezW.Impact of Event Scale: a measure of subjective stress. Psychosom Med. 1979;41:209–218.
40.
GuyW.ECDEU Assessment manual for psychopharmacology. Rev ed. Washington, DC: US Department of Health, Education, and Welfare; 1976.
41.
HamiltonM.A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62.
42.
LiebowitzMR. Social phobia. Mod Probl Pharmacopsychiatry. 1987;22:141–173.
43.
BuysseDJReynoldsCF3rd, MonkTH, . The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28:193–213.
44.
GermainAHallMKrakowB. A brief sleep scale for posttraumatic stress disorder: Pittsburgh Sleep Quality Index Addendum for PTSD. J Anxiety Disord. 2005;19:233–244.
45.
KesslerRCSonnegaABrometE. Post-traumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry. 1995;52:1048–1060.
